Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Clinically Relevant Resistance in Cancer Chemotherapy

Clinically Relevant Resistance in Cancer Chemotherapy

Andersson, Borje
Murray, David

Hardcover

Series: Cancer Treatment and Research, Book 112

Medical Reference

ISBN10: 1402072007
ISBN13: 9781402072000
Publisher: Springer Pg
Published: Oct 31 2002
Pages: 380
Weight: 1.76
Height: 1.10 Width: 6.26 Depth: 9.66
Language: English
Over the last several decades, the introduction of new chemotherapeutic drugs and drug combinations has resulted in increased long- term remission rates in several important tumor types. These include childhood leukemia, adult leukemias and lymphomas, as well as testicular and trophoblastic tumors. The addition of high-dose chemotherapy with growth factor and hemopoietic stem cell support has increased clinical remission rates even further. For the majority of patients with some of the more common malignancies, however, palliation (rather than cure) is still the most realistic goal of chemotherapy for metastatic disease. The failure of chemotherapy to cure metastatic cancer is commonly referred to among clinicians as drug resistance. This phenomenon can, however, often be viewed as the survival of malignant cells that resulted from a failure to deliver an effective drug dose to the (cellular) target because of anyone of or combination of a multitude of individual factors. Clinically, this treatment failure is often viewed as the rapid occurrence of resistance at the single cell level. However, in experimental systems, stable drug resistance is usually relatively slow to emerge.

1 different editions

Also available

Also in

Medical Reference

View All